Relay Therapeutics amends TD Securities equity distribution deal, lifts potential sales to $462.98 million
RLAY•Sale methods updated
The amendment also updates the permitted sale methods to include negotiated transactions such as block trades.
Prospectus supplement due
A prospectus supplement reflecting the amendment is slated to be filed within two business days.
Amended at-the-market sales agreement
Relay Therapeutics amended its at-the-market common stock sales agreement with TD Securities, raising the maximum offering size to $462.98 million from $250 million.
